Revenue
1.56 billion USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 1557204000 USD Source
Annual consolidated revenue for 2025: about USD 5.141B, using the latest reported figures. The previous period, 2024, was about USD 4.241B.
1.56 billion USD
2026 Q3 · USD
-45.49%
2026 Q3 · %
-675 million USD
2026 Q3 · USD
3275881000 USD
19094000000 Unit12
204002500 shares
4.01% · 7.87 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-29.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 4.24 billion
–
Current period
USD 5.14 billion
–
5141242000 − 4241217000 = 900025000 USD
4241217000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source5141242000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 32.62 million
–
Current period
USD 1.29 billion
–
1286650000 − 32615000 = 1254035000 USD
32615000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1286650000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
USD 335.34 million
–
Current period
USD 1.41 billion
–
1413498000 − 335337000 = 1078161000 USD
335337000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1413498000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | 2666702000 | 2930378000 Derived | -263676000 | 32021000 Derived | -295697000 | Unavailable | Source
|
| 2021 2021-01-01 – 2021-12-31 | 2986267000 | 2400490000 Derived | 585777000 | -362804000 Derived | 948581000 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 3394635000 | 2815195000 Derived | 579440000 | 238780000 Derived | 340660000 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 3695649000 | 3075124000 Derived | 620525000 | 22926000 Derived | 597599000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 4241217000 | 4179851000 Derived | 61366000 | 28751000 Derived | 32615000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 5141242000 | 3626383000 Derived | 1514859000 | 228209000 Derived | 1286650000 | Unavailable | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Revenue | 2666702000 |
|
| 2021 | Revenue | 2986267000 |
|
| 2022 | Revenue | 3394635000 |
|
| 2023 | Revenue | 3695649000 |
|
| 2024 | Revenue | 4241217000 |
|
| 2025 | Revenue | 5141242000 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Year over year | No prior comparable period |
|
| 2021 | Year over year | 12% |
|
| 2022 | Year over year | 13.7% |
|
| 2023 | Year over year | 8.9% |
|
| 2024 | Year over year | 14.8% |
|
| 2025 | Year over year | 21.2% |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020 | Operating margin | -9.9% |
|
| 2021 | Operating margin | 19.6% |
|
| 2022 | Operating margin | 17.1% |
|
| 2023 | Operating margin | 16.8% |
|
| 2024 | Operating margin | 1.4% |
|
| 2025 | Operating margin | 29.5% |
|
| 2020 | Net margin | -11.1% |
|
| 2021 | Net margin | 31.8% |
|
| 2022 | Net margin | 10% |
|
| 2023 | Net margin | 16.2% |
|
| 2024 | Net margin | 0.8% |
|
| 2025 | Net margin | 25% |
|
| 2020 | Free cash flow margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Operating cash flow | -124599000 |
|
| 2021 | Operating cash flow | 749488000 |
|
| 2022 | Operating cash flow | 969941000 |
|
| 2023 | Operating cash flow | 496487000 |
|
| 2024 | Operating cash flow | 335337000 |
|
| 2025 | Operating cash flow | 1413498000 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2020 | Free cash flow | Unavailable |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2021 | Liabilities / assets | 23.6% |
|
| 2022 | Liabilities / assets | 25.2% |
|
| 2023 | Liabilities / assets | 23.5% |
|
| 2024 | Liabilities / assets | 36.7% |
|
| 2025 | Liabilities / assets | 25.7% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2020-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2021 | Current assets / current liabilities | 3.65× |
|
| 2022 | Current assets / current liabilities | 3.54× |
|
| 2023 | Current assets / current liabilities | 3.75× |
|
| 2024 | Current assets / current liabilities | 1.97× |
|
| 2025 | Current assets / current liabilities | 3.32× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | −USD 295.7 million Exact valueExact value: -295697000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 124.6 million Exact valueExact value: -124599000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | USD 948.58 million Exact valueExact value: 948581000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 749.49 million Exact valueExact value: 749488000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | USD 340.66 million Exact valueExact value: 340660000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 969.94 million Exact valueExact value: 969941000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | USD 597.6 million Exact valueExact value: 597599000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 496.49 million Exact valueExact value: 496487000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | USD 32.62 million Exact valueExact value: 32615000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 335.34 million Exact valueExact value: 335337000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | USD 1.29 billion Exact valueExact value: 1286650000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.41 billion Exact valueExact value: 1413498000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
265 filings · 7,262 latest values · 7,262 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000879169, 879169, INCY, edgar:879169
Also known as INCYTE CORP, INCYTE CORPORATION, INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC